IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022
July 26 2022 - 8:04AM
Business Wire
The Company to host an earnings conference call
via webcast
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”)
(NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and
technology company, today announced that it will host a conference
call to discuss its financial results and recent business
highlights for fourth quarter and full fiscal year 2022, on Friday,
July 29, 2022, at 10:30 am Eastern Time. The financial results will
be issued in a press release prior to the call.
ImmunoPrecise management will host the conference call followed
by a pre-submitted question-and-answer period. Investors interested
in submitting questions ahead of the call are encouraged to email
the Company’s investor relations contact.
Conference Call:
Date: Friday, July 29, 2022 Time: 10:30 am Eastern time
Participant Info:
Conference ID: 9236374 Participant Toll-Free Dial-In Number: 1
(888) 550-5658 Participant Toll Dial-In Number: 1 (646)
960-0289
Attendee URL: https://events.q4inc.com/attendee/831812822
The conference call will be webcast live and available for
replay via a link provided in the Events section of the company’s
IR pages at https://www.immunoprecise.com/investors.
Please call the conference telephone number five minutes prior
to the start time. An operator will register your name and
organization.
Anyone listening to the call is encouraged to read the company's
periodic reports on file with the Toronto Stock Exchange and
Securities and Exchange Commission, including the discussion of
risk factors and historical results of operations and financial
condition in those reports.
ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotherapeutic,
innovation-powered company that supports its business partners in
their quest to discover and develop novel antibodies against a
broad range of target classes and diseases. The Company offers a
hybrid of services and programs with advanced platforms and
technologies to optimize antibody discovery and development,
against rare and/or challenging epitopes. For further information,
visit www.immunoprecise.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220726005644/en/
Investor contact: investors@immunoprecise.com
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Jul 2023 to Jul 2024